Salvage Chemotherapy Followed by Autologous Stem-Cell Transplantation Using Targeted Busulfan for Refractory Diffuse Large B-Cell Lymphoma With Dialysis-Dependent End-Stage Renal Disease

A treatment strategy of salvage chemotherapy and autologous stem-cell transplantation (ASCT) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients receiving hemodialysis has not yet been established. We conducted a pharmacokinetic analysis in a patient with refractory DLBCL with end-stage renal disease and successfully administered adjusted dosing of salvage chemotherapies and a conditioning regimen in ASCT without any adverse events.

Source: Clinical Lymphoma, Myeloma and Leukemia - November 6, 2019 Category: Hematology Authors: Kaoru Morita, Masahiro Ashizawa, Yumiko Toda, Takashi Ikeda, Shin-ichiro Kawaguchi, Shoko Ito, Shin-ichi Ochi, Takashi Nagayama, Kiyomi Mashima, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Ryoko Yamasaki, Chihiro Yamamoto, Kaoru Hatano, Shin-ichiro Fu Tags: Original Study Source Type: research